BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Chronic Obstructive Pulmonary Disease readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Chronic Obstructive P
 ulmonary Disease\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07705737-1328@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rademikibart: Phase 2 readout est. (NCT07705737)
DESCRIPTION:Rademikibart\, phase 2\, Chronic Obstructive Pulmonary Disease.
 \nStudy: Rademikibart IV for Acute Asthma and COPD Exacerbation\nEstimated
  primary completion: December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/rademikibart#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07705737
URL:https://assetmemo.bio/drug/rademikibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06491043-1552@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Solizmestrocel: Phase 2 readout est. (NCT06491043)
DESCRIPTION:Solizmestrocel\, phase 2\, Chronic Obstructive Pulmonary Diseas
 e.\nStudy: Treatment of Chronic Obstructive Pulmonary Disease by Infusion 
 of Allogenic Mesenchymal Stem Cells\nEstimated primary completion: 30 Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/solizmestr
 ocel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06491043
URL:https://assetmemo.bio/drug/solizmestrocel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07464587-1558@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:TQC3721: Phase 3 readout est. (NCT07464587)
DESCRIPTION:TQC3721\, phase 3\, Chronic Obstructive Pulmonary Disease.\nStu
 dy: Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate
 -to-Severe Chronic Obstructive Pulmonary Disease\nEstimated primary comple
 tion: February 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tqc3721#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07464587
URL:https://assetmemo.bio/drug/tqc3721#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07147946-1558@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:TQC3721: Phase 3 readout est. (NCT07147946)
DESCRIPTION:TQC3721\, phase 3\, Chronic Obstructive Pulmonary Disease.\nStu
 dy: Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Pati
 ents With Moderate-to-Severe Chronic Obstructive Pulmonary Disease\nEstima
 ted primary completion: March 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/tqc3721#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07147946
URL:https://assetmemo.bio/drug/tqc3721#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05270525-1526@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Ohtuvayre (ensifentrine): Phase 2 readout est. (NCT05270525)
DESCRIPTION:Ohtuvayre (ensifentrine)\, phase 2\, Chronic Obstructive Pulmon
 ary Disease.\nStudy: Effect of Ensifentrine (MK-5884/RPL554) on Sputum Mar
 kers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5
 884-023/RPL554-CO-207)\nEstimated primary completion: 1 March 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ensifentrine#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05270525
URL:https://assetmemo.bio/drug/ensifentrine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668518-1544@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:KIT2014: Phase 1/2 readout est. (NCT07668518)
DESCRIPTION:KIT2014\, phase 1/2\, Chronic Obstructive Pulmonary Disease.\nS
 tudy: A Study of the Safety\, Tolerability\, Pharmacokinetics and Efficacy
  of KIT2014 in Patients With Moderate to Severe COPD\nEstimated primary co
 mpletion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/kit2014#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07668518
URL:https://assetmemo.bio/drug/kit2014#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07658339-1539@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270611
DTEND;VALUE=DATE:20270612
SUMMARY:HSK39004: Phase 3 readout est. (NCT07658339)
DESCRIPTION:HSK39004\, phase 3\, Chronic Obstructive Pulmonary Disease.\nSt
 udy: A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39
 004 Inhalation Suspension in Patients With COPD\nEstimated primary complet
 ion: 11 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hs
 k39004#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07658339
URL:https://assetmemo.bio/drug/hsk39004#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05878769-1435@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:astegolimab: Phase 3 readout est. (NCT05878769)
DESCRIPTION:astegolimab\, phase 3\, Chronic Obstructive Pulmonary Disease.\
 nStudy: A Study to Evaluate the Long-Term Safety of Astegolimab in Partici
 pants With Chronic Obstructive Pulmonary Disease (COPD)\nEstimated primary
  completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/astegolimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05878769
URL:https://assetmemo.bio/drug/astegolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07425210-1539@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:HSK39004: Phase 2 readout est. (NCT07425210)
DESCRIPTION:HSK39004\, phase 2\, Chronic Obstructive Pulmonary Disease.\nSt
 udy: Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPD\
 nEstimated primary completion: July 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/hsk39004#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07425210
URL:https://assetmemo.bio/drug/hsk39004#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07418736-1336@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Ocankitug: Phase 2 readout est. (NCT07418736)
DESCRIPTION:Ocankitug\, phase 2\, Chronic Obstructive Pulmonary Disease.\nS
 tudy: A Phase II Study of CM326 in Subjects With Moderate to Severe Chroni
 c Obstructive Pulmonary Disease\nEstimated primary completion: 1 July 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ocankitug#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07418736
URL:https://assetmemo.bio/drug/ocankitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082738-11161@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:AZD6793: Phase 2 readout est. (NCT07082738)
DESCRIPTION:AZD6793\, phase 2\, Chronic Obstructive Pulmonary Disease.\nStu
 dy: A Study to Investigate the Effect of AZD6793 in Participants With Mode
 rate to Very Severe Chronic Obstructive Pulmonary Disease\nEstimated prima
 ry completion: 31 August 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/azd6793#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07082738
URL:https://assetmemo.bio/drug/azd6793#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07583849-1539@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:HSK39004: Phase 3 readout est. (NCT07583849)
DESCRIPTION:HSK39004\, phase 3\, Chronic Obstructive Pulmonary Disease.\nSt
 udy: A Multicenter\, Randomized\, Double-blind\, Placebo-controlled\, Para
 llel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment
  of COPD\nEstimated primary completion: 30 September 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/hsk39004#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07583849
URL:https://assetmemo.bio/drug/hsk39004#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06981078-1535@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:verekitug: Phase 2 readout est. (NCT06981078)
DESCRIPTION:verekitug\, phase 2\, Chronic Obstructive Pulmonary Disease.\nS
 tudy: A Study to Assess the Efficacy and Safety of Verekitug in Participan
 ts With COPD\nEstimated primary completion: October 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/verekitug#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06981078
URL:https://assetmemo.bio/drug/verekitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07292714-1276@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:9MW1911: Phase 2 readout est. (NCT07292714)
DESCRIPTION:9MW1911\, phase 2\, Chronic Obstructive Pulmonary Disease.\nStu
 dy: A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmo
 nary Disease (COPD)\nEstimated primary completion: December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/9mw1911#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07292714
URL:https://assetmemo.bio/drug/9mw1911#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07519499-1515@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:XKH001: Phase 2 readout est. (NCT07519499)
DESCRIPTION:XKH001\, phase 2\, Chronic Obstructive Pulmonary Disease.\nStud
 y: Phase II Clinical Study to Evaluate the Efficacy and Safety of XKH001 I
 njection\nEstimated primary completion: 1 December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/xkh001#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07519499
URL:https://assetmemo.bio/drug/xkh001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06283966-7606@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20271203
DTEND;VALUE=DATE:20271204
SUMMARY:Breztri Aerosphere (Budesonide/glycopyrrolate/formoterol fumarate):
  Phase 3 readout est. (NCT06283966)
DESCRIPTION:Breztri Aerosphere (Budesonide/glycopyrrolate/formoterol fumara
 te)\, phase 3\, Chronic Obstructive Pulmonary Disease.\nStudy: A Study Eva
 luating the Efficacy of Budesonide\, Glycopyrronium and Formoterol Fumarat
 e Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive
  Pulmonary Disease\nEstimated primary completion: 3 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/budesonide-glycopyrrolate-fo
 rmoterol-fumarate#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06283966
URL:https://assetmemo.bio/drug/budesonide-glycopyrrolate-formoterol-fumarat
 e#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07646587-1536@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20271217
DTEND;VALUE=DATE:20271218
SUMMARY:WIN378: Phase 2 readout est. (NCT07646587)
DESCRIPTION:WIN378\, phase 2\, Chronic Obstructive Pulmonary Disease.\nStud
 y: A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
 \nEstimated primary completion: 17 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/win378#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07646587
URL:https://assetmemo.bio/drug/win378#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07634367-1539@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20271224
DTEND;VALUE=DATE:20271225
SUMMARY:HSK39004: Phase 3 readout est. (NCT07634367)
DESCRIPTION:HSK39004\, phase 3\, Chronic Obstructive Pulmonary Disease.\nSt
 udy: Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in CO
 PD\nEstimated primary completion: 24 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/hsk39004#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07634367
URL:https://assetmemo.bio/drug/hsk39004#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07349524-1551@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:RSS0343: Phase 2 readout est. (NCT07349524)
DESCRIPTION:RSS0343\, phase 2\, Chronic Obstructive Pulmonary Disease.\nStu
 dy: A Study to Evaluate the Efficacy and Safety of RSS0343 Tablets in Pati
 ents With Chronic Obstructive Pulmonary Disease\nEstimated primary complet
 ion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rss0
 343#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07349524
URL:https://assetmemo.bio/drug/rss0343#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06980142-1337@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280317
DTEND;VALUE=DATE:20280318
SUMMARY:CM512: Phase 2 readout est. (NCT06980142)
DESCRIPTION:CM512\, phase 2\, Chronic Obstructive Pulmonary Disease.\nStudy
 : A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive
  Pulmonary Disease\nEstimated primary completion: 17 March 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/cm512#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06980142
URL:https://assetmemo.bio/drug/cm512#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07759245-822@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07759245)
DESCRIPTION:Brenipatide\, phase 2\, Chronic Obstructive Pulmonary Disease.\
 nStudy: A Study of Brenipatide (LY3537031) in Adult Participants With Mode
 rate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)\nEstimated pri
 mary completion: May 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/brenipatide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07759245
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07402551-1553@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:RC1416: Phase 2 readout est. (NCT07402551)
DESCRIPTION:RC1416\, phase 2\, Chronic Obstructive Pulmonary Disease.\nStud
 y: Phase II Study of RC1416 Injection in COPD\nEstimated primary completio
 n: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rc141
 6#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 402551
URL:https://assetmemo.bio/drug/rc1416#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07828353-1554@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:REGEND001: Phase 3 readout est. (NCT07828353)
DESCRIPTION:REGEND001\, phase 3\, Chronic Obstructive Pulmonary Disease.\nS
 tudy: A Clinical Study of REGEND001 for the Treatment of Chronic Obstructi
 ve Pulmonary Disease (COPD)\nEstimated primary completion: September 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/regend001#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07828353
URL:https://assetmemo.bio/drug/regend001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06959095-1527@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20281213
DTEND;VALUE=DATE:20281214
SUMMARY:Depemokimab: Phase 3 readout est. (NCT06959095)
DESCRIPTION:Depemokimab\, phase 3\, Chronic Obstructive Pulmonary Disease.\
 nStudy: Depemokimab as an Extended Treatment Duration Biologic in Adults W
 ith Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation\n
 Estimated primary completion: 13 December 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/depemokimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06959095
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06961214-1527@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20281213
DTEND;VALUE=DATE:20281214
SUMMARY:Depemokimab: Phase 3 readout est. (NCT06961214)
DESCRIPTION:Depemokimab\, phase 3\, Chronic Obstructive Pulmonary Disease.\
 nStudy: Depemokimab as an Extended Treatment Duration Biologic in Adults W
 ith Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (
 ENDURA-2)\nEstimated primary completion: 13 December 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/depemokimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06961214
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07566195-1426@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20281229
DTEND;VALUE=DATE:20281230
SUMMARY:tozorakimab: Phase 3 readout est. (NCT07566195)
DESCRIPTION:tozorakimab\, phase 3\, Chronic Obstructive Pulmonary Disease.\
 nStudy: Long-term Safety and Tolerability of Tozorakimab in Patients With 
 COPD and History of Exacerbations\nEstimated primary completion: 29 Decemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/tozorakimab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0756
 6195
URL:https://assetmemo.bio/drug/tozorakimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07915791-3551@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20290307
DTEND;VALUE=DATE:20290308
SUMMARY:Felcorekibart: Phase 2 readout est. (NCT07915791)
DESCRIPTION:Felcorekibart\, phase 2\, Chronic Obstructive Pulmonary Disease
 .\nStudy: A Study to Assess the Efficacy and Safety of Co-administration o
 f GSK3862995B With GSK5784283 in Adult Participants With Moderate to Sever
 e Chronic Obstructive Pulmonary Disease (COPD)\nEstimated primary completi
 on: 7 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fel
 corekibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07915791
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06878261-1507@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20290313
DTEND;VALUE=DATE:20290314
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT06878261)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Chronic Obstructive Pulmonar
 y Disease.\nStudy: A Study to Investigate the Efficacy and Safety of Tezep
 elumab in Adult Participants With Moderate to Very Severe COPD (D5241C0000
 7)\nEstimated primary completion: 13 March 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tezepelumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06878261
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06883305-1507@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20290313
DTEND;VALUE=DATE:20290314
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT06883305)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Chronic Obstructive Pulmonar
 y Disease.\nStudy: A Study to Investigate the Efficacy and Safety of Tezep
 elumab in Adult Participants With Moderate to Very Severe COPD (D5241C0000
 6)\nEstimated primary completion: 13 March 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tezepelumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06883305
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07177339-1527@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20290402
DTEND;VALUE=DATE:20290403
SUMMARY:Depemokimab: Phase 3 readout est. (NCT07177339)
DESCRIPTION:Depemokimab\, phase 3\, Chronic Obstructive Pulmonary Disease.\
 nStudy: eValuating the Efficacy and Safety of InitiatinG depemokImab earLy
  therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Infl
 ammation\nEstimated primary completion: 2 April 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/depemokimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07177339
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874815-1526@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20290429
DTEND;VALUE=DATE:20290430
SUMMARY:Ohtuvayre (ensifentrine): Phase 3 readout est. (NCT07874815)
DESCRIPTION:Ohtuvayre (ensifentrine)\, phase 3\, Chronic Obstructive Pulmon
 ary Disease.\nStudy: Ensifentrine (MK-5884) Study for the Prevention of Ch
 ronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a 
 History of Moderate or Severe Exacerbations While Receiving Standard of Ca
 re (SOC) (MK-5884-031/RPL554/ENHANCE-3)\nEstimated primary completion: 29 
 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ensifentr
 ine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07874815
URL:https://assetmemo.bio/drug/ensifentrine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07780656-3551@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20290720
DTEND;VALUE=DATE:20290721
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07780656)
DESCRIPTION:Felcorekibart\, phase 3\, Chronic Obstructive Pulmonary Disease
 .\nStudy: A Study to Investigate the Efficacy and Safety of GSK5784283 (Fe
 lcorekibart) Compared With Placebo in Participants With Moderate to Very S
 evere COPD (PERSIST COPD-2)\nEstimated primary completion: 20 July 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/felcorekibart#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07780656
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07780669-3551@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20290720
DTEND;VALUE=DATE:20290721
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07780669)
DESCRIPTION:Felcorekibart\, phase 3\, Chronic Obstructive Pulmonary Disease
 .\nStudy: A Study to Investigate the Efficacy and Safety of GSK5784283 (Fe
 lcorekibart) Compared With Placebo in Participants With Moderate to Very S
 evere COPD (PERSIST COPD-1)\nEstimated primary completion: 20 July 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/felcorekibart#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07780669
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07190209-1424@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20291127
DTEND;VALUE=DATE:20291128
SUMMARY:lunsekimig: Phase 3 readout est. (NCT07190209)
DESCRIPTION:lunsekimig\, phase 3\, Chronic Obstructive Pulmonary Disease.\n
 Study: Efficacy\, Safety\, and Tolerability Study of Lunsekimig Compared W
 ith Placebo in Adult Participants With Inadequately Controlled Chronic Obs
 tructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenoty
 pe\nEstimated primary completion: 27 November 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/lunsekimig#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07190209
URL:https://assetmemo.bio/drug/lunsekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07190222-1424@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20291127
DTEND;VALUE=DATE:20291128
SUMMARY:lunsekimig: Phase 3 readout est. (NCT07190222)
DESCRIPTION:lunsekimig\, phase 3\, Chronic Obstructive Pulmonary Disease.\n
 Study: Efficacy\, Safety\, and Tolerability Study of Lunsekimig Compared W
 ith Placebo in Adult Participants With Inadequately Controlled Chronic Obs
 tructive Pulmonary Disease (COPD)\, Characterized by an Eosinophilic Pheno
 type\nEstimated primary completion: 27 November 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/lunsekimig#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07190222
URL:https://assetmemo.bio/drug/lunsekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06946953-1554@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:REGEND001: Phase 1/2 readout est. (NCT06946953)
DESCRIPTION:REGEND001\, phase 1/2\, Chronic Obstructive Pulmonary Disease.\
 nStudy: REGEND001 Autologous Basal Layer Stem Cell Transplantation for Chr
 onic Obstructive Pulmonary Disease (COPD): A Translational Application Stu
 dy\nEstimated primary completion: 31 December 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/regend001#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06946953
URL:https://assetmemo.bio/drug/regend001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07363694-1455@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20301024
DTEND;VALUE=DATE:20301025
SUMMARY:tilrekimig: Phase 2/3 readout est. (NCT07363694)
DESCRIPTION:tilrekimig\, phase 2/3\, Chronic Obstructive Pulmonary Disease.
 \nStudy: A Study to Learn About the Study Medicine Called PF-07275315 in P
 eople With Moderate to Severe Chronic Obstructive Pulmonary Disease\nEstim
 ated primary completion: 24 October 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tilrekimig#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07363694
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07793409-1424@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20310723
DTEND;VALUE=DATE:20310724
SUMMARY:lunsekimig: Phase 3 readout est. (NCT07793409)
DESCRIPTION:lunsekimig\, phase 3\, Chronic Obstructive Pulmonary Disease.\n
 Study: A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig
  in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)\n
 Estimated primary completion: 23 July 2031. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/lunsekimig#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07793409
URL:https://assetmemo.bio/drug/lunsekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06547333-1335@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20320429
DTEND;VALUE=DATE:20320430
SUMMARY:stapokibart: Phase 2/3 readout est. (NCT06547333)
DESCRIPTION:stapokibart\, phase 2/3\, Chronic Obstructive Pulmonary Disease
 .\nStudy: A Study of CM310 in Subjects With Moderate to Severe Chronic Obs
 tructive Pulmonary Disease\nEstimated primary completion: 29 April 2032. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/stapokibart#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06547333
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07839884-1455@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20340421
DTEND;VALUE=DATE:20340422
SUMMARY:tilrekimig: Phase 3 readout est. (NCT07839884)
DESCRIPTION:tilrekimig\, phase 3\, Chronic Obstructive Pulmonary Disease.\n
 Study: A Continuation Study of Tilrekimig in Adults With Moderate-to-Sever
 e Long-Term Breathing Difficulty\, Known by the Medical Term of Chronic Ob
 structive Pulmonary Disease (COPD) to Learn About This Medicine When Used 
 for a Long Period of Time\nEstimated primary completion: 21 April 2034. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/tilrekimig#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07839884
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
